Author
Listed:
- Zhen Ning
(Dalian Institute of Chemical Physics, Chinese Academy of Sciences
The First Affiliated Hospital of Dalian Medical University, Dalian Medical University
Liaoning Key Laboratory of Molecular Targeted Drugs in Hepatobiliary and Pancreatic Cancer)
- Xin Guo
(Dalian Institute of Chemical Physics, Chinese Academy of Sciences
The First Affiliated Hospital of Dalian Medical University, Dalian Medical University)
- Xiaolong Liu
(Dalian Institute of Chemical Physics, Chinese Academy of Sciences)
- Chang Lu
(Dalian Institute of Chemical Physics, Chinese Academy of Sciences
The First Affiliated Hospital of Dalian Medical University, Dalian Medical University)
- Aman Wang
(The First Affiliated Hospital of Dalian Medical University, Dalian Medical University
Liaoning Key Laboratory of Molecular Targeted Drugs in Hepatobiliary and Pancreatic Cancer)
- Xiaolin Wang
(Dalian Institute of Chemical Physics, Chinese Academy of Sciences)
- Wen Wang
(Dalian Institute of Chemical Physics, Chinese Academy of Sciences)
- Huan Chen
(Dalian Institute of Chemical Physics, Chinese Academy of Sciences)
- Wangshu Qin
(Dalian Institute of Chemical Physics, Chinese Academy of Sciences)
- Xinyu Liu
(Dalian Institute of Chemical Physics, Chinese Academy of Sciences)
- Lina Zhou
(Dalian Institute of Chemical Physics, Chinese Academy of Sciences)
- Chi Ma
(The First Affiliated Hospital of Dalian Medical University, Dalian Medical University
Liaoning Key Laboratory of Molecular Targeted Drugs in Hepatobiliary and Pancreatic Cancer)
- Jian Du
(The First Affiliated Hospital of Dalian Medical University, Dalian Medical University
Liaoning Key Laboratory of Molecular Targeted Drugs in Hepatobiliary and Pancreatic Cancer)
- Zhikun Lin
(Dalian Institute of Chemical Physics, Chinese Academy of Sciences
The First Affiliated Hospital of Dalian Medical University, Dalian Medical University
Liaoning Key Laboratory of Molecular Targeted Drugs in Hepatobiliary and Pancreatic Cancer)
- Haifeng Luo
(The First Affiliated Hospital of Dalian Medical University, Dalian Medical University
Liaoning Key Laboratory of Molecular Targeted Drugs in Hepatobiliary and Pancreatic Cancer)
- Wuxiyar Otkur
(Dalian Institute of Chemical Physics, Chinese Academy of Sciences)
- Huan Qi
(Dalian Institute of Chemical Physics, Chinese Academy of Sciences)
- Di Chen
(Dalian Institute of Chemical Physics, Chinese Academy of Sciences)
- Tian Xia
(Dalian Institute of Chemical Physics, Chinese Academy of Sciences)
- Jiwei Liu
(The First Affiliated Hospital of Dalian Medical University, Dalian Medical University
Liaoning Key Laboratory of Molecular Targeted Drugs in Hepatobiliary and Pancreatic Cancer)
- Guang Tan
(The First Affiliated Hospital of Dalian Medical University, Dalian Medical University
Liaoning Key Laboratory of Molecular Targeted Drugs in Hepatobiliary and Pancreatic Cancer)
- Guowang Xu
(Dalian Institute of Chemical Physics, Chinese Academy of Sciences)
- Hai-long Piao
(Dalian Institute of Chemical Physics, Chinese Academy of Sciences
University of Chinese Academy of Sciences
China Medical University)
Abstract
Elevated de novo lipogenesis is considered to be a crucial factor in hepatocellular carcinoma (HCC) development. Herein, we identify ubiquitin-specific protease 22 (USP22) as a key regulator for de novo fatty acid synthesis, which directly interacts with deubiquitinates and stabilizes peroxisome proliferator-activated receptor gamma (PPARγ) through K48-linked deubiquitination, and in turn, this stabilization increases acetyl-CoA carboxylase (ACC) and ATP citrate lyase (ACLY) expressions. In addition, we find that USP22 promotes de novo fatty acid synthesis and contributes to HCC tumorigenesis, however, this tumorigenicity is suppressed by inhibiting the expression of PPARγ, ACLY, or ACC in in vivo tumorigenesis experiments. In HCC, high expression of USP22 positively correlates with PPARγ, ACLY or ACC expression, and associates with a poor prognosis. Taken together, we identify a USP22-regulated lipogenesis mechanism that involves the PPARγ-ACLY/ACC axis in HCC tumorigenesis and provide a rationale for therapeutic targeting of lipogenesis via USP22 inhibition.
Suggested Citation
Zhen Ning & Xin Guo & Xiaolong Liu & Chang Lu & Aman Wang & Xiaolin Wang & Wen Wang & Huan Chen & Wangshu Qin & Xinyu Liu & Lina Zhou & Chi Ma & Jian Du & Zhikun Lin & Haifeng Luo & Wuxiyar Otkur & Hu, 2022.
"USP22 regulates lipidome accumulation by stabilizing PPARγ in hepatocellular carcinoma,"
Nature Communications, Nature, vol. 13(1), pages 1-18, December.
Handle:
RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-29846-9
DOI: 10.1038/s41467-022-29846-9
Download full text from publisher
References listed on IDEAS
- Bin Liu & Shangwen Jiang & Min Li & Xuelian Xiong & Mingrui Zhu & Duanzhuo Li & Lei Zhao & Lili Qian & Linhui Zhai & Jing Li & Han Lu & Shengnan Sun & Jiandie Lin & Yan Lu & Xiaoying Li & Minjia Tan, 2018.
"Proteome-wide analysis of USP14 substrates revealed its role in hepatosteatosis via stabilization of FASN,"
Nature Communications, Nature, vol. 9(1), pages 1-12, December.
- Ganna Panasyuk & Catherine Espeillac & Céline Chauvin & Ludivine A. Pradelli & Yasuo Horie & Akira Suzuki & Jean-Sebastien Annicotte & Lluis Fajas & Marc Foretz & Francisco Verdeguer & Marco Pontoglio, 2012.
"PPARγ contributes to PKM2 and HK2 expression in fatty liver,"
Nature Communications, Nature, vol. 3(1), pages 1-9, January.
Full references (including those not matched with items on IDEAS)
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.
- Minxuan Xu & Jun Tan & Xin Liu & Li Han & Chenxu Ge & Yujie Zhang & Fufang Luo & Zhongqin Wang & Xiaoqin Xue & Liangyin Xiong & Xin Wang & Qinqin Zhang & Xiaoxin Wang & Qin Tian & Shuguang Zhang & Qin, 2023.
"Tripartite motif containing 26 prevents steatohepatitis progression by suppressing C/EBPδ signalling activation,"
Nature Communications, Nature, vol. 14(1), pages 1-22, December.
- Dongni Shi & Xianqiu Wu & Yunting Jian & Junye Wang & Chengmei Huang & Shuang Mo & Yue Li & Fengtian Li & Chao Zhang & Dongsheng Zhang & Huizhong Zhang & Huilin Huang & Xin Chen & Y. Alan Wang & Chuyo, 2022.
"USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer,"
Nature Communications, Nature, vol. 13(1), pages 1-18, December.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-29846-9. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.